NU 13H05: A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia

Trial Profile

NU 13H05: A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Chronic lymphocytic leukaemia vaccine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors XEME Biopharma
  • Most Recent Events

    • 02 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 02 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 02 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top